meiragtx holdings plc - MGTX
MGTX
Close Chg Chg %
7.24 0.14 1.93%
Open Market
7.38
+0.14 (1.93%)
Volume: 124.69K
Last Updated:
Jan 13, 2026, 3:01 PM EDT
Company Overview: meiragtx holdings plc - MGTX
MGTX Key Data
| Open $7.24 | Day Range 7.06 - 7.39 |
| 52 Week Range 4.55 - 9.73 | Market Cap $582.75M |
| Shares Outstanding 80.49M | Public Float 58.25M |
| Beta 1.39 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.11 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 419.97K |
MGTX Performance
| 1 Week | -2.29% | ||
| 1 Month | -18.83% | ||
| 3 Months | -6.58% | ||
| 1 Year | 15.65% | ||
| 5 Years | -55.75% |
MGTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About meiragtx holdings plc - MGTX
MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.
MGTX At a Glance
MeiraGTx Holdings Plc
655 Third Avenue
New York, New York 10017
| Phone | 1-646-860-7985 | Revenue | 33.28M | |
| Industry | Biotechnology | Net Income | -147,791,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 137.419% | |
| Fiscal Year-end | 12 / 2025 | Employees | 381 | |
| View SEC Filings |
MGTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.777 |
| Price to Book Ratio | 7.039 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.684 |
| Enterprise Value to Sales | 12.211 |
| Total Debt to Enterprise Value | 0.209 |
MGTX Efficiency
| Revenue/Employee | 87,346.457 |
| Income Per Employee | -387,902.887 |
| Receivables Turnover | 3.131 |
| Total Asset Turnover | 0.091 |
MGTX Liquidity
| Current Ratio | 2.032 |
| Quick Ratio | 2.026 |
| Cash Ratio | 1.705 |
MGTX Profitability
| Gross Margin | -10.036 |
| Operating Margin | -493.44 |
| Pretax Margin | -444.097 |
| Net Margin | -444.097 |
| Return on Assets | -40.606 |
| Return on Equity | -143.484 |
| Return on Total Capital | -96.833 |
| Return on Invested Capital | -79.496 |
MGTX Capital Structure
| Total Debt to Total Equity | 125.02 |
| Total Debt to Total Capital | 55.559 |
| Total Debt to Total Assets | 31.435 |
| Long-Term Debt to Equity | 119.044 |
| Long-Term Debt to Total Capital | 52.904 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Meiragtx Holdings Plc - MGTX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 37.70M | 15.92M | 14.02M | 33.28M | |
Sales Growth
| +142.25% | -57.77% | -11.95% | +137.42% | |
Cost of Goods Sold (COGS) incl D&A
| 7.87M | 8.72M | 13.73M | 36.62M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 7.87M | 8.72M | 13.73M | 12.83M | |
Depreciation
| 7.57M | 8.52M | 13.43M | 12.53M | |
Amortization of Intangibles
| 300.00K | 200.00K | 300.00K | 300.00K | |
COGS Growth
| - | +10.80% | +57.40% | +166.71% | |
Gross Income
| 29.83M | 7.20M | 287.00K | (3.34M) | |
Gross Income Growth
| - | -75.87% | -96.01% | -1,263.76% | |
Gross Profit Margin
| +79.12% | +45.21% | +2.05% | -10.04% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 103.02M | 123.55M | 137.35M | 160.87M | |
Research & Development
| 66.83M | 85.53M | 103.48M | 119.18M | |
Other SG&A
| 36.19M | 38.03M | 33.86M | 41.69M | |
SGA Growth
| +39.32% | +19.93% | +11.17% | +17.13% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | (499.00K) | - |
EBIT after Unusual Expense
| (73.19M) | (116.36M) | (136.56M) | (164.21M) | |
Non Operating Income/Expense
| (6.08M) | (8.31M) | 65.78M | 29.69M | |
Non-Operating Interest Income
| 212.00K | 777.00K | 2.27M | 4.14M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 288.00K | 4.95M | 13.24M | 13.27M | |
Interest Expense Growth
| +106.89% | +1,617.36% | +167.79% | +0.20% | |
Gross Interest Expense
| 288.00K | 4.95M | 13.24M | 13.27M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (79.56M) | (129.62M) | (84.03M) | (147.79M) | |
Pretax Income Growth
| -37.19% | -62.91% | +35.17% | -75.89% | |
Pretax Margin
| -211.03% | -814.16% | -599.46% | -444.10% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (79.56M) | (129.62M) | (84.03M) | (147.79M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (79.56M) | (129.62M) | (84.03M) | (147.79M) | |
Net Income Growth
| -37.19% | -62.91% | +35.17% | -75.89% | |
Net Margin Growth
| -211.03% | -814.16% | -599.46% | -444.10% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (79.56M) | (129.62M) | (84.03M) | (147.79M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (79.56M) | (129.62M) | (84.03M) | (147.79M) | |
EPS (Basic)
| -1.8025 | -2.869 | -1.4876 | -2.1167 | |
EPS (Basic) Growth
| -17.25% | -59.17% | +48.15% | -42.29% | |
Basic Shares Outstanding
| 44.14M | 45.18M | 56.49M | 69.82M | |
EPS (Diluted)
| -1.8025 | -2.869 | -1.4876 | -2.1167 | |
EPS (Diluted) Growth
| -17.25% | -59.17% | +48.15% | -42.29% | |
Diluted Shares Outstanding
| 44.14M | 45.18M | 56.49M | 69.82M | |
EBITDA
| (65.32M) | (107.63M) | (123.33M) | (151.38M) | |
EBITDA Growth
| -11.88% | -64.78% | -14.59% | -22.75% | |
EBITDA Margin
| -173.26% | -676.08% | -879.87% | -454.89% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 26.875 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.58 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -1.129 | |
| Last Quarter’s Earnings | -0.585 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.698 | Next Fiscal Year Estimate | -0.817 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 7 | 3 |
| Mean Estimate | -0.58 | -0.58 | -1.13 | -0.82 |
| High Estimates | -0.51 | -0.53 | 0.89 | 0.36 |
| Low Estimate | -0.65 | -0.66 | -2.59 | -2.14 |
| Coefficient of Variance | -10.72 | -10.71 | -117.62 | -153.85 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Meiragtx Holdings Plc - MGTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Meiragtx Holdings Plc - MGTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 9, 2025 | Alexandria Forbes PRESIDENT & CEO; Director | 1,408,983 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.34 per share | 7,523,969.22 |
| Apr 8, 2025 | Stuart Naylor CHIEF DEV. OFFICER | 100,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Robert K. Zeldin CHIEF MEDICAL OFFICER | 90,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Richard Giroux CFO & COO | 950,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Robert J. Wollin GENERAL COUNSEL AND SECRETARY | 100,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Alexandria Forbes PRESIDENT & CEO; Director | 1,456,483 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.3 per share | 10,632,325.90 |
| Feb 26, 2025 | Alexandria Forbes PRESIDENT & CEO; Director | 125,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Stuart Naylor CHIEF DEV. OFFICER | 623,291 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.3 per share | 4,550,024.30 |
| Feb 26, 2025 | Stuart Naylor CHIEF DEV. OFFICER | 50,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Robert K. Zeldin CHIEF MEDICAL OFFICER | 136,520 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.3 per share | 996,596.00 |
| Feb 26, 2025 | Robert K. Zeldin CHIEF MEDICAL OFFICER | 15,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Richard Giroux CFO & COO | 906,495 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.3 per share | 6,617,413.50 |
| Feb 26, 2025 | Richard Giroux CFO & COO | 120,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Robert J. Wollin GENERAL COUNSEL AND SECRETARY | 31,146 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.3 per share | 227,365.80 |
| Feb 26, 2025 | Robert J. Wollin GENERAL COUNSEL AND SECRETARY | 22,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |